65,437 trials
Bacterial Enteritis
Primary: The Amounts of Radioactivity Excreted in Urine and Faeces — 78.0; 6.08; 84.1 percentage of administered dose
Multiple Myeloma
Primary: Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bortezomib, Dexamethasone, Doxorubicin, and ALCAR — 53 percentage of…
Myopia
Primary: Cosmetic Appearance Preference — 8; 9; 4; 5 participants
Video Laryngoscopic Device Usage in Novice Users
Primary: Intubation Success on First Attempt as Measured by End Tidal Carbon Dioxide — 24; 33 participants
Healthy
Primary: Number of Participants With Local and Systemic Adverse Events — 207 participants
Coronary Occlusion · Thrombosis (Stent Thrombosis) · Vascular Disease
Primary: In-stent Late Loss (LL) — 0.19; 0.21 Millimeter
Gingivitis
Primary: Plaque Index — 2.3; 2.5; 1.9; 2 units on a scale
Invasive Breast Carcinoma · Recurrent Breast Carcinoma · Stage III Breast Cancer AJCC v6
Primary: Progression-free Survival — 20.2; 15.6 months
Insomnia · Sleeplessness · Transient Insomnia
Primary: Latency to Persistent Sleep (LPS) — 48.14; 58.84 minutes — p=.1275
Turner Syndrome
Primary: Most Mature Height Standard Deviation Score (SDS) — -1.37; -1.60 standard deviation score
Prostate Cancer
Primary: Relapse-free Survival — 13; 10 months
Immune System Diseases · Oxidative Stress
Primary: Change in Interleukin-6 — 4.60; 4.58; 4.50; 5.27 pg/mL
Systemic Lupus Erythematosus
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 101; 27 participants
Chronic Lymphocytic Leukemia
Primary: Complete Remission (CR) Rate of FCR3 in Treatment-naïve Participants With Chronic Lymphocytic Leukemia (CLL) at 6 Months — 75 Percentage of Participants
Lymphoma
Primary: Participant Response Rate According to the International Working Group (IWG) Response Criteria for Non Hodgkin's Lymphoma (NHL), Cheson 1999 — 86.8; 91.6 Percentage of…